CA3170058A1 - Vaccine against african swine fever virus infection - Google Patents
Vaccine against african swine fever virus infection Download PDFInfo
- Publication number
- CA3170058A1 CA3170058A1 CA3170058A CA3170058A CA3170058A1 CA 3170058 A1 CA3170058 A1 CA 3170058A1 CA 3170058 A CA3170058 A CA 3170058A CA 3170058 A CA3170058 A CA 3170058A CA 3170058 A1 CA3170058 A1 CA 3170058A1
- Authority
- CA
- Canada
- Prior art keywords
- cat
- ep402r
- tat
- protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12061—Methods of inactivation or attenuation
- C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2003292.6 | 2020-03-06 | ||
| GB2003289.2 | 2020-03-06 | ||
| GBGB2003292.6A GB202003292D0 (en) | 2020-03-06 | 2020-03-06 | Vaccine |
| GBGB2003289.2A GB202003289D0 (en) | 2020-03-06 | 2020-03-06 | Vaccine |
| GBGB2005880.6A GB202005880D0 (en) | 2020-04-22 | 2020-04-22 | Vaccine |
| GB2005878.0 | 2020-04-22 | ||
| GBGB2005878.0A GB202005878D0 (en) | 2020-04-22 | 2020-04-22 | Vaccine |
| GB2005880.6 | 2020-04-22 | ||
| GBGB2013541.4A GB202013541D0 (en) | 2020-08-28 | 2020-08-28 | Vaccine |
| GB2013541.4 | 2020-08-28 | ||
| PCT/GB2021/050562 WO2021176236A1 (en) | 2020-03-06 | 2021-03-05 | Vaccine against african swine fever virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3170058A1 true CA3170058A1 (en) | 2021-09-10 |
Family
ID=74870840
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3170058A Pending CA3170058A1 (en) | 2020-03-06 | 2021-03-05 | Vaccine against african swine fever virus infection |
| CA3170043A Pending CA3170043A1 (en) | 2020-03-06 | 2021-03-05 | Vaccine against african swine fever virus infection |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3170043A Pending CA3170043A1 (en) | 2020-03-06 | 2021-03-05 | Vaccine against african swine fever virus infection |
Country Status (13)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024110451A1 (en) * | 2022-11-22 | 2024-05-30 | Intervet International B.V. | Attenuated african swine fever virus and use thereof in vaccine compositions |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201910794D0 (en) * | 2019-07-29 | 2019-09-11 | Pirbright Inst | Vaccine |
| EP4565269A2 (en) * | 2022-08-04 | 2025-06-11 | Malcolm, Thomas | Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus |
| WO2024057048A1 (en) * | 2022-09-12 | 2024-03-21 | Consejo Superior De Investigaciones Científicas | Attenuated african swine fever virus and use thereof in vaccine compositions |
| CN120936878A (zh) * | 2022-11-22 | 2025-11-11 | 马德里黄金标准诊断公司 | 用于区分感染asfv与asfv疫苗接种的动物的方法 |
| CN117224669B (zh) * | 2023-07-31 | 2024-07-30 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015091322A1 (en) * | 2013-12-18 | 2015-06-25 | Boehringer Ingelheim Vetmedica Gmbh | Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals |
| GB201410971D0 (en) * | 2014-06-19 | 2014-08-06 | Pirbright Inst The | Vaccine |
| US9528094B2 (en) * | 2014-11-10 | 2016-12-27 | The United States Of America, As Represented By The Secretary Of Agriculture | Attenuated African swine fever virus vaccine based in the deletion of MGF genes |
| CN110551695A (zh) * | 2019-08-14 | 2019-12-10 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 非洲猪瘟病毒四基因缺失弱毒株及其应用 |
-
2021
- 2021-03-05 WO PCT/GB2021/050560 patent/WO2021176234A1/en not_active Ceased
- 2021-03-05 BR BR112022016893A patent/BR112022016893A8/pt unknown
- 2021-03-05 MX MX2022010372A patent/MX2022010372A/es unknown
- 2021-03-05 CN CN202180019982.7A patent/CN116133680A/zh active Pending
- 2021-03-05 CN CN202180019234.9A patent/CN115397463A/zh active Pending
- 2021-03-05 WO PCT/GB2021/050561 patent/WO2021176235A1/en not_active Ceased
- 2021-03-05 US US17/905,490 patent/US20240293525A1/en active Pending
- 2021-03-05 EP EP21711339.8A patent/EP4114454A1/en active Pending
- 2021-03-05 EP EP21711338.0A patent/EP4114453A1/en active Pending
- 2021-03-05 PH PH1/2022/552084A patent/PH12022552084A1/en unknown
- 2021-03-05 WO PCT/GB2021/050562 patent/WO2021176236A1/en not_active Ceased
- 2021-03-05 CA CA3170058A patent/CA3170058A1/en active Pending
- 2021-03-05 JP JP2022552880A patent/JP2023516713A/ja active Pending
- 2021-03-05 PH PH1/2022/552086A patent/PH12022552086A1/en unknown
- 2021-03-05 EP EP21711340.6A patent/EP4114455A1/en active Pending
- 2021-03-05 US US17/905,488 patent/US20230117978A1/en active Pending
- 2021-03-05 CA CA3170043A patent/CA3170043A1/en active Pending
- 2021-03-05 CN CN202180019437.8A patent/CN115605223A/zh active Pending
- 2021-03-05 BR BR112022016891A patent/BR112022016891A2/pt unknown
- 2021-03-05 AU AU2021231402A patent/AU2021231402A1/en active Pending
- 2021-03-05 AU AU2021229654A patent/AU2021229654A1/en active Pending
- 2021-03-05 KR KR1020227034853A patent/KR20230013017A/ko active Pending
- 2021-03-05 KR KR1020227034852A patent/KR20230013016A/ko active Pending
- 2021-03-05 JP JP2022552870A patent/JP2023516709A/ja active Pending
- 2021-03-05 US US17/905,492 patent/US20230124042A1/en active Pending
- 2021-03-05 MX MX2022010373A patent/MX2022010373A/es unknown
-
2022
- 2022-09-05 CL CL2022002412A patent/CL2022002412A1/es unknown
- 2022-09-05 CL CL2022002416A patent/CL2022002416A1/es unknown
- 2022-10-03 CO CONC2022/0014152A patent/CO2022014152A2/es unknown
- 2022-10-05 CO CONC2022/0014256A patent/CO2022014256A2/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024110451A1 (en) * | 2022-11-22 | 2024-05-30 | Intervet International B.V. | Attenuated african swine fever virus and use thereof in vaccine compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230117978A1 (en) | 2023-04-20 |
| WO2021176234A1 (en) | 2021-09-10 |
| BR112022016891A2 (pt) | 2023-01-24 |
| CL2022002412A1 (es) | 2023-03-03 |
| CN115397463A (zh) | 2022-11-25 |
| CN115605223A (zh) | 2023-01-13 |
| CL2022002416A1 (es) | 2023-03-03 |
| WO2021176235A1 (en) | 2021-09-10 |
| JP2023516709A (ja) | 2023-04-20 |
| US20230124042A1 (en) | 2023-04-20 |
| EP4114453A1 (en) | 2023-01-11 |
| CO2022014256A2 (es) | 2022-12-30 |
| KR20230013016A (ko) | 2023-01-26 |
| WO2021176236A1 (en) | 2021-09-10 |
| MX2022010372A (es) | 2023-01-19 |
| JP2023516713A (ja) | 2023-04-20 |
| EP4114455A1 (en) | 2023-01-11 |
| PH12022552084A1 (en) | 2024-02-26 |
| MX2022010373A (es) | 2023-01-19 |
| BR112022016893A8 (pt) | 2023-02-28 |
| KR20230013017A (ko) | 2023-01-26 |
| CA3170043A1 (en) | 2021-09-10 |
| AU2021231402A1 (en) | 2022-11-03 |
| AU2021229654A1 (en) | 2022-11-03 |
| US20240293525A1 (en) | 2024-09-05 |
| BR112022016893A2 (pt) | 2023-01-24 |
| CO2022014152A2 (es) | 2023-02-16 |
| PH12022552086A1 (en) | 2023-11-20 |
| EP4114454A1 (en) | 2023-01-11 |
| CN116133680A (zh) | 2023-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3170043A1 (en) | Vaccine against african swine fever virus infection | |
| Moormann et al. | Molecular cloning and nucleotide sequence of hog cholera virus strain Brescia and mapping of the genomic region encoding envelope protein E1 | |
| EP3394085B1 (en) | Feline calicivirus vaccine | |
| CA3170422A1 (en) | Coronavirus disease (covid-19) vaccine | |
| CN109310750B (zh) | 编码传染性喉气管炎病毒和传染性法氏囊病病毒抗原的重组非致病性马立克氏病病毒构建体 | |
| CN113943714A (zh) | 一种猫杯状病毒毒株及其应用 | |
| WO2017132332A1 (en) | Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes | |
| CA3234653A1 (en) | Influenza vaccines | |
| US20150306209A1 (en) | CANINE PARVOVIRUS TYPE 2c ISOLATES AND METHODS OF USE | |
| JP2023522154A5 (cg-RX-API-DMAC7.html) | ||
| CN107635579A (zh) | 非天然发生的猪生殖和呼吸综合征病毒(prrsv)和使用方法 | |
| Thiele et al. | Analysis of the entire nucleotide sequence of the cryptic plasmid QpH1 from Coxiella burnetii | |
| CN103589693B (zh) | 一种表达ibdv vp2和法氏囊素三肽嵌合蛋白重组火鸡疱疹病毒 | |
| WO1993024646A1 (fr) | Antigene de mycoplasme aviaire, son gene, vecteur recombine contenant ledit gene, et vaccin prepare a l'aide de celui-ci | |
| AU2019463018B2 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
| Lederman et al. | Detection of bovine parvovirus proteins homologous to the nonstructural NS-1 proteins of other autonomous parvoviruses | |
| Yu et al. | Molecular characteristics of full-length genomic segment A of three infectious bursal disease viruses in China: two attenuated strains and one virulent field strain | |
| RU2843901C1 (ru) | Вакцина против инфекции вируса африканской чумы свиней | |
| RU2805193C1 (ru) | Вакцинный вирус свиного репродуктивно-респираторного синдрома | |
| Podgoreanu et al. | Sequencing and Partial Molecular Characterization of BAB-TMP, the Babes, Strain of the Fixed Rabies Virus Adapted for Multiplication in Cell Lines. Viruses 2023, 15, 1851 | |
| JP2025513753A (ja) | ワントゥーストップ(one-to-stop)弱毒化SARS-CoV-2ウイルス | |
| WO2023164625A2 (en) | Modified plant virus system for delivery of nucleic acids into mammalian cells | |
| JPH06253852A (ja) | Ccvワクチン | |
| JP2023166633A (ja) | インフルエンザウイルス抑制用の融合タンパク質およびこれを含む医薬組成物 | |
| T El-Gendy et al. | Molecular characterization and VP1 sequence analysis of Foot and Mouth disease new virus strains isolated during 2015-2017 in Beni-Suef, Egypt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250225 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250225 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250225 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250228 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250301 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250301 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250301 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250304 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250304 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250304 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250508 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260303 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260303 |